Seawolf Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$100M
- Investors
-
8
Seawolf Therapeutics General Information
Description
Operator of a gene therapy company based in San Diego, California. The company develops next-generation non-viral genetic medicines, enabling patients living with debilitating unmet medical needs to get suitable therapeutics.
Contact Information
Corporate Office
- 9880 Campus Point Drive
- Suite 210
- San Diego, CA 92121
- United States
Corporate Office
- 9880 Campus Point Drive
- Suite 210
- San Diego, CA 92121
- United States
Seawolf Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 16-Nov-2026 | $100M | Completed | Startup | ||
| 1. Seed Round | Completed | Startup |
Seawolf Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Seawolf Therapeutics Patents
Seawolf Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026029828-A2 | Unsaturated ionizable lipids and nanoparticle compositions thereof | Pending | 14-May-2024 | ||
| WO-2026029828-A3 | Unsaturated ionizable lipids and nanoparticle compositions thereof | Pending | 14-May-2024 | ||
| AU-2025235582-A1 | Enhanced nuclear delivery of dna and compositions for use in practicing the same | Pending | 11-Mar-2024 | ||
| WO-2025193592-A2 | Enhanced nuclear delivery of dna and compositions for use in practicing the same | Pending | 11-Mar-2024 | ||
| WO-2025193592-A3 | Enhanced nuclear delivery of dna and compositions for use in practicing the same | Pending | 11-Mar-2024 | C12N15/87 |
Seawolf Therapeutics Signals
Seawolf Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| CRISPR Therapeutics | Corporation | Minority | ||
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| MPM BioImpact | Venture Capital | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority |
Seawolf Therapeutics FAQs
-
When was Seawolf Therapeutics founded?
Seawolf Therapeutics was founded in 2021.
-
Where is Seawolf Therapeutics headquartered?
Seawolf Therapeutics is headquartered in San Diego, CA.
-
What is the size of Seawolf Therapeutics?
Seawolf Therapeutics has 32 total employees.
-
What industry is Seawolf Therapeutics in?
Seawolf Therapeutics’s primary industry is Drug Discovery.
-
Is Seawolf Therapeutics a private or public company?
Seawolf Therapeutics is a Private company.
-
What is the current valuation of Seawolf Therapeutics?
The current valuation of Seawolf Therapeutics is .
-
What is Seawolf Therapeutics’s current revenue?
The current revenue for Seawolf Therapeutics is .
-
How much funding has Seawolf Therapeutics raised over time?
Seawolf Therapeutics has raised $124T.
-
Who are Seawolf Therapeutics’s investors?
Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company Foundation, MPM BioImpact, and Novartis Venture Fund are 5 of 8 investors who have invested in Seawolf Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process